{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["36(9)"],"submitter":["Kong F"],"pubmed_abstract":["<h4>Background and aim</h4>This single-arm, open-label, multicenter, phase 3 trial evaluated the efficacy and safety of seraprevir, an hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) inhibitor, combined with sofosbuvir for treating Chinese patients with chronic HCV infection without cirrhosis.<h4>Methods</h4>Treatment-naive or interferon-experienced adult patients without cirrhosis were treated with a universal, combinational regimen of seraprevir 100 mg, twice daily and sofosbuvir 400 mg, once daily, for 12 or 24 weeks. The primary efficacy endpoint was sustained virologic response at week 12 after treatment (SVR12).<h4>Results</h4>Overall, 205 patients with genotype 1 HCV infection without cirrhosis were enrolled from 23 sites, 202 of whom completed the full treatment and pos"],"journal":["Journal of gastroenterology and hepatology"],"pagination":["2375-2382"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8518536"],"repository":["biostudies-literature"],"pubmed_title":["Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial."],"pmcid":["PMC8518536"],"pubmed_authors":["Wen X","Huang C","Lin S","Su M","Liu Q","Zhang L","Wei W","Wu G","Wang J","Wang L","Jia J","Ning Q","Xing H","Niu J","Wang X","Wang Z","Wu X","Li G","Niu D","Tong L","Chen L","Kong F","Zheng S","Tong Z","Yan X","Li X","Zhang Y","Lin J","Zhu Q","Xin Y"],"additional_accession":[]},"is_claimable":false,"name":"Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial.","description":"<h4>Background and aim</h4>This single-arm, open-label, multicenter, phase 3 trial evaluated the efficacy and safety of seraprevir, an hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) inhibitor, combined with sofosbuvir for treating Chinese patients with chronic HCV infection without cirrhosis.<h4>Methods</h4>Treatment-naive or interferon-experienced adult patients without cirrhosis were treated with a universal, combinational regimen of seraprevir 100 mg, twice daily and sofosbuvir 400 mg, once daily, for 12 or 24 weeks. The primary efficacy endpoint was sustained virologic response at week 12 after treatment (SVR12).<h4>Results</h4>Overall, 205 patients with genotype 1 HCV infection without cirrhosis were enrolled from 23 sites, 202 of whom completed the full treatment and pos","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-18T17:29:07.734Z","creation":"2025-02-19T00:19:08.965Z"},"accession":"S-EPMC8518536","cross_references":{"pubmed":["33491236"],"doi":["10.1111/jgh.15412"]}}